Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 146 |
| Active Pipeline (Recruiting Now) | 80 (56) |
| Completed vs Stopped Early | 36 / 30 (20.6%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | 118 |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 7 |
| University of Pennsylvania Abramson Cancer Center | Philadelphia, PA | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06996652 | An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Pers | Phase II | RECRUITING |
| NCT06923527 | Circulating Tumor DNA | Phase II | RECRUITING |
| NCT03907046 | Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase III | RECRUITING |
| NCT04924322 | Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies | Phase II/III | RECRUITING |
| NCT03456843 | Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Yale University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.